An honest look at the opportunity in medication-free neurostimulation detox
Neuro Recovery Institute is raising the capital to open Portland's first clinic focused solely on medication-free, neurostimulation-based opioid detox. We are looking for partners who want to be the first to bring this FDA-cleared technology to the Pacific Northwest — and who value a company that will always tell the truth to its patients and its backers.
We will start with the honest part: this is an early-stage venture. We are pre-revenue and pre-licensing, and the returns are not guaranteed. What follows is the real market context and the economic logic — with sources — so you can judge it for yourself.
Market sizing from third-party market-research estimates (directional, methodologies vary). Grant figure per State Opioid Response program reporting. Sources: Future Market Insights, Market Data Forecast.
The core therapy is a single-use, per-patient neurostimulation device — a modest consumable cost relative to a reimbursed detox episode, with no expensive daily pharmacotherapy to dispense.
Because detox is medication-free, the model avoids the DEA/opioid-treatment-program dispensing infrastructure that methadone and buprenorphine clinics require. State facility licensing is still required.
To our knowledge, no other Portland clinic focuses solely on neurostimulation detox — a genuine first-mover position in a large, growing regional market.
In published cost studies of opioid-use-disorder treatment episodes, the detoxification phase accounts for the majority of total cost — the exact stage this model is built to deliver. (AJMC)
The table below is an illustration of the economic logic only — not a forecast, and not based on signed contracts or a licensed, operating facility. Real figures depend on payer mix, negotiated rates, patient volume, staffing, and Oregon licensing.
| Factor | Why it matters |
|---|---|
| Reimbursed detox episode | Detox is billable through established H-codes; commercial payers frequently reimburse behavioral health above Medicare rates. |
| Per-patient device cost | A single-use neurostimulation device is a bounded, predictable consumable cost per patient. |
| Staffing | The largest ongoing cost; a lean, protocol-driven clinical model is central to margin. |
| Throughput | A ~10-day device course allows planned patient scheduling and capacity utilization. |
| Aftercare linkage | Coordinating naltrexone and outpatient follow-up can extend the care relationship beyond detox. |
We deliberately do not publish specific profit-per-patient figures here, because doing so responsibly requires signed payer rates and an operating facility we do not yet have. We are happy to walk qualified, interested investors through our detailed model directly.
We would rather lose an investor by being honest than win one by overselling. The neurostimulation field has enough of that already.
We are open to conversations with investors who want to be the first to bring this technology to the Northwest. Reach out for a direct discussion and our detailed materials.
Email investors@neurorecoveryinstitute.org
or call (844) 674-6789
Important disclosures. This page is for general informational purposes only. It is not an offer to sell, or a solicitation of an offer to buy, any security or investment, and it does not constitute investment, financial, legal, tax, or medical advice. Any investment in Neuro Recovery Institute, if and when offered, would be made only through formal offering documents and may be limited to accredited investors under applicable securities laws. Statements about the future — including market projections, plans, and the economic logic described above — are forward-looking and inherently uncertain; actual results may differ materially. Market figures are drawn from third-party sources believed to be reliable but are not independently verified. Prospective investors should conduct their own due diligence and consult their own advisors.